Metallomix develops disease-modifying therapies that utilize isotope-selective modulation to repair cellular functions disrupted by inflammation and oxidative stress, particularly in neurodegenerative diseases and cancers. Their approach focuses on the therapeutic application of stable isotopes, such as zinc-64, to restore cellular homeostasis and improve immune response without compromising safety.
Funding
$534.2K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including neurodegenerative disorders, cancers, and metabolic syndromes, are characterized by cellular dysfunction resulting from inflammation, oxidative stress, and metallome deficiencies. Current treatments often manage symptoms without addressing the underlying causes related to isotopic dysfractionation within cells.
Solution
Metallomix is developing disease-modifying therapies based on isotope-selective modulation to restore cellular functions disrupted by inflammation and oxidative stress. Their approach uses stable isotopes, such as zinc-64, to target and repair imbalances in cellular homeostasis, inflammatory responses, and oxidative processes without compromising safety. By modulating cellular isotopic signatures, Metallomix aims to influence critical biological processes, including protein synthesis, DNA repair, and mitochondrial function. Their drug candidates are designed to address the root causes of disease by holistically influencing these processes, offering potential treatments for oncological, neurodegenerative, metabolic, and autoimmune diseases.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases, cancers, metabolic disorders, and autoimmune conditions, as well as the healthcare providers who treat them.
Features
- Focus on non-radioactive isotopes to modulate cellular processes
- Drug candidates in clinical trials for malignant neoplasms and CLL (Aspazin)
- Pre-clinical programs for Type 2 Diabetes, NAFLD (Omazinc), Parkinson's, Lewy Body Dementia, and Alzheimer's Disease (Isotozin)
- Animal studies being designed for Multiple Sclerosis and Hashimoto's disease
- Aims to reduce inflammation and oxidative stress via multiple mechanisms of action
- ISM Drug Development Platform integrates Metallomics and pharmaceutical development